Healius logo

HLS - Healius Share Price

A$3.92 0.1  1.8%

Last Trade - 5:10am

Mid Cap
Market Cap £1.36bn
Enterprise Value £2.27bn
Revenue £898.3m
Position in Universe 175th / 1843
Unlock HLS Revenue
Relative Strength (%)
1m -0.74%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -3.99%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
1,580 1,642 1,659 1,705 1,562 1,585 1,848 1,814 +0.06%
-12.0 -9.0 +163.8 -72.6 -25.7 +27.4 +69.2 -10.8
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 30 June 2020, Healius Ltdrevenues increased 1% to A$1.58B. Net income beforeextraordinary items increased 26% to A$72M. Revenuesreflect Pathology segment increase of 3% to A$1.16B, DayHospital segment increase of 40% to A$65.4M. Net incomebenefited from Operating leases decrease of 84% to A$30.9M(expense), Net Financial Income/Expense - Other increasefrom A$0K to A$23.6M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


HLS Revenue Unlock HLS Revenue

Net Income

HLS Net Income Unlock HLS Revenue

Normalised EPS

HLS Normalised EPS Unlock HLS Revenue

PE Ratio Range

HLS PE Ratio Range Unlock HLS Revenue

Dividend Yield Range

HLS Dividend Yield Range Unlock HLS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
HLS EPS Forecasts Unlock HLS Revenue
Profile Summary

Healius Ltd, formerly Primary Health Care Limited is a medical center operator. The Company also operates as a provider of diagnostic imaging services; a provider of pathology services, and a provider of health technology. It provides a range of services and facilities to healthcare practitioners, and its medical center operations include the provision of day surgery and in vitro fertilization services by healthcare practitioners. Its segments include Medical Centres, Pathology, Imaging, Health Technology and Other. The Medical Centres division provides services and facilities to general practitioners, specialists and other healthcare providers, and includes Transport Health. The Pathology division provides pathology services. The Imaging division provides imaging and scanning services from standalone imaging sites and from within the consolidated entity's medical centers. The Health Technology division develops, sells and supports health-related software products.

Last Annual June 30th, 2020
Last Interim June 30th, 2020
Incorporated May 17, 1994
Public Since July 3, 1998
No. of Shareholders: 13,455
No. of Employees: 12,500
Sector Healthcare
Industry Healthcare Providers & Services
Index S&P/ASX All Ordinaries , S&P/ASX 200 , S&P/ASX 300 , ASX Small Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 622,743,000
Free Float (0.0%)
Eligible for
HLS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for HLS
Upcoming Events for HLS
Wednesday 24th February, 2021 Estimate
Half Year 2021 Healius Ltd Earnings Release
Frequently Asked Questions for Healius
What is the Healius share price?

As of 5:10am, shares in Healius are trading at A$3.92, giving the company a market capitalisation of £1.36bn. This share price information is delayed by 15 minutes.

How has the Healius share price performed this year?

Shares in Healius are currently trading at A$3.92 and the price has moved by 30.95% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Healius price has moved by 35.88% over the past year.

What are the analyst and broker recommendations for Healius?

Of the analysts with advisory recommendations for Healius, there are there are currently 0 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Healius is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Healius next release its financial results?

Healius is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Healius dividend yield?

The Healius dividend yield is 0.68% based on the trailing twelve month period.

Does Healius pay a dividend?

Last year, Healius paid a total dividend of 0.03, and it currently has a trailing dividend yield of 0.68%. Looking ahead, Healius has not announced an ex-dividend date yet.

When does Healius next pay dividends?

Healius has yet to annouce their ex-dividend date. The historic dividend yield on Healius shares is currently 0.68%.

How do I buy Healius shares?

To buy shares in Healius you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Healius?

Shares in Healius are currently trading at A$3.92, giving the company a market capitalisation of £1.36bn.

Where are Healius shares listed? Where are Healius shares listed?

Here are the trading details for Healius:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: HLS
What kind of share is Healius?

Based on an overall assessment of its quality, value and momentum, Healius is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Healius share price forecast 2021?

Shares in Healius are currently priced at A$3.92. At that level they are trading at 3.12% discount to the analyst consensus target price of 0.00.

Analysts covering Healius currently have a consensus Earnings Per Share (EPS) forecast of 0.203 for the next financial year.

How can I tell whether the Healius share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Healius. Over the past six months, the relative strength of its shares against the market has been 9.83%. At the current price of A$3.92, shares in Healius are trading at 20.25% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Healius PE Ratio?

The Healius PE ratio based on its reported earnings over the past 12 months is 32.08. The shares are currently trading at A$3.92.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Healius?

Healius's management team is headed by:

Paul Jones - NID
Robert Hubbard - NEC
Gordon Davis - NID
Maxine Jaquet - CFO
Mark Neeham - OTH
Janet Payne - OTH
Dean Lewsam - CEX
Malcolm Parmenter - CEO
Sally Louise Evans - NID
John McKechnie - CEX
Alison Stephenson - SEC
Jenny Macdonald - NID
Ben Korst - CEX
Peter Wilson - OTH
Scott Beattie - CEX
Who are the major shareholders of Healius?

Here are the top five shareholders of Healius based on the size of their shareholding:

Jangho Group Co Ltd Corporation
Percentage owned: 15.88% (98.9m shares)
Yarra Funds Management Limited Investment Advisor
Percentage owned: 6.92% (43.1m shares)
Harris Associates L.P. Investment Advisor/Hedge Fund
Percentage owned: 5.65% (35.2m shares)
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund
Percentage owned: 5.61% (35.0m shares)
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund
Percentage owned: 2.54% (15.8m shares)
Similar to HLS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.